

PRESS RELEASE

ALGENEX appoints new Strategic Advisory Board (SAB)

Advisors include recognized industry leaders in international healthcare

Madrid (Spain), March 13, 2019 – ALGENEX SL (the “company”), a private biotechnology company delivering disruptive technologies for recombinant biologics production, today announces the formation of its Strategic Advisory Board (SAB). The newly-formed SAB will work closely with ALGENEX’s management team to further advance its progress in the animal health industry and support the company’s move into human health. The SAB will also guide the company’s expansion and development of its own product portfolio. Dr. René Aerts, Jean Stéphenne and Dr. Claudia D’Augusta will join the SAB.

“We are proud to welcome such well-recognized industry leaders to our newly formed Strategic Advisory Board,” said José M. Escribano, CSO of ALGENEX. “Their commitment to the company is a clear validation of the strength and potential impact of our technologies and their combined experience will be a great asset as we work to make ALGENEX the preferred partner for companies whose business requires efficient, robust and scalable protein expression systems.”

Dr. René Aerts is the founder of RA Consultancy, supporting top tier Animal Health companies in M&A, R&D and manufacturing strategy. He retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previously held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International.

Jean Stéphenne is a highly-experienced life sciences executive who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies. He was Chairman of TiGenix until its acquisition by Takeda in 2018 and previously served as a member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines).

Dr. Claudia D’Augusta currently serves as CFO of the Swiss biotechnology company Therachon and as venture partner at Ysios Capital Partners in Spain. Prior to this she was as CFO at TiGenix, where she led the company through its merger with Cellerix, the approval of its stem cell therapy product Alofisel, its Nasdaq IPO and finally its €520M acquisition by Takeda.

For further information, please contact:

Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

About ALGENEX

ALGENEX is a private biotechnology company developing disruptive technologies for the production of protein-based recombinant biologics.

ALGENEX' first two platforms, TopBac® and CrisBio®, have both been developed on the back of baculovirus-based expression systems and have demonstrated their ability to optimize protein production by increasing the yield and quality of the proteins as well as in succeeding to produce proteins that are difficult-to-express.

The use of ALGENEX' technologies significantly increases the speed and versatility of expression of a wide variety of protein families and thereby allowing the acceleration of the development times of protein-based pharmaceutical or diagnostic products.

For more information, please visit <http://www.algenex.com>